Leadership Overview
Cadila Pharmaceuticals has 10 executives leading key functions including operations, API development, corporate affairs, business unit management, branded sales, human resources, clinical research, regional expansion, plantation management, and marketing.
Dedicated to advancing global health through innovation-led drug discovery, Cadila Pharmaceuticals delivers affordable healthcare solutions across 45 therapeutic areas while maintaining a strong commitment to sustainability and community well-being.
Dedicated to advancing global health through innovation-led drug discovery, Cadila Pharmaceuticals delivers affordable healthcare solutions across 45 therapeutic areas while maintaining a strong commitment to sustainability and community well-being.
Leadership Roles at Cadila Pharmaceuticals
Kamalesh Kalidasan - Chief Operating Officer
Kamalesh Kalidasan, the Chief Operating Officer at Cadila Pharmaceuticals, directs internal manufacturing processes and supply chain efficiency. Overseeing the production of over 850 products, the Chief Operating Officer ensures that formulation development meets rigorous international quality standards. This leadership role involves optimizing resource allocation across 12 specialties to maintain cost-effectiveness in a competitive global market. By streamlining cross-functional workflows, Kamalesh Kalidasan directly impacts the scalability of pharmaceutical output. The Chief Operating Officer coordinates with R&D teams to integrate new drug discoveries into existing production lines, ensuring consistent supply for diverse therapeutic areas. Through meticulous oversight of operational infrastructure, Kalidasan secures the company's ability to deliver affordable healthcare solutions across more than 100 countries. This focus on operational excellence supports the broader mission of making health simpler and safer for patients worldwide.
Matthew Zrebiec - Chief Operating Officer, API and CDMO
Matthew Zrebiec, the Chief Operating Officer, API and CDMO at Cadila Pharmaceuticals, manages the active pharmaceutical ingredient division and contract manufacturing services. Overseeing complex chemical synthesis and formulation development, the Chief Operating Officer, API and CDMO drives the expansion of contract manufacturing capabilities for external partners. This leadership role involves aligning technical R&D with market demand to secure long-term growth in the CDMO sector. By enhancing the efficiency of API production, Matthew Zrebiec directly supports the company's ability to provide high-quality components for oncology and cardiology therapies. The Chief Operating Officer, API and CDMO coordinates with global regulatory bodies to ensure compliance across all manufacturing sites. Through strategic management of these specialized business units, Zrebiec strengthens the company's position as a reliable partner in the global pharmaceutical supply chain, ultimately facilitating broader access to essential medical treatments.
Raj Vyas - Group President, Corporate & Public Affairs
Raj Vyas, the Group President, Corporate & Public Affairs at Cadila Pharmaceuticals, directs external relations and government engagement strategies. Overseeing the company's reputation and policy advocacy, the Group President, Corporate & Public Affairs ensures alignment with international healthcare standards and local regulatory requirements. This leadership role involves managing stakeholder communications to support the company's mission of providing affordable medicine. By fostering partnerships with public health organizations, Raj Vyas directly impacts the company's ability to influence positive health outcomes in diverse markets. The Group President, Corporate & Public Affairs coordinates with internal departments to communicate the impact of innovation-led drug discovery to the public. Through proactive engagement with policymakers and industry groups, Vyas secures the company's standing as a leader in pharmaceutical sustainability and community well-being. This strategic focus on public affairs facilitates the company's growth across its extensive global footprint.
Debesh Das - President BSBU
Debesh Das, the President BSBU at Cadila Pharmaceuticals, manages the strategic direction of the business unit. Overseeing market penetration and product lifecycle management, the President BSBU ensures that therapeutic offerings meet the specific needs of patients in target regions. This leadership role involves analyzing market trends to guide the development of new pharmaceutical solutions. By optimizing the performance of the business unit, Debesh Das directly contributes to the company's revenue growth and market share. The President BSBU coordinates with R&D and sales teams to ensure that product launches align with the company's broader innovation goals. Through rigorous performance monitoring and strategic planning, Das drives the success of the business unit within the competitive pharmaceutical landscape. This focus on specialized business management supports the company's commitment to delivering high-quality, accessible healthcare solutions across its diverse portfolio of 45 therapies.
Suresh Gupta - President, Branded Business
Suresh Gupta, the President, Branded Business at Cadila Pharmaceuticals, directs the commercial strategy for the company's branded product portfolio. Overseeing brand positioning and market expansion, the President, Branded Business ensures that high-value therapies reach healthcare providers and patients effectively. This leadership role involves managing the lifecycle of key products across oncology, cardiology, and pediatrics. By driving brand awareness and market adoption, Suresh Gupta directly impacts the company's financial performance and therapeutic reach. The President, Branded Business coordinates with marketing and sales teams to execute campaigns that highlight the efficacy and safety of the company's drug innovations. Through strategic oversight of the branded portfolio, Gupta strengthens the company's market presence and supports the mission of providing accessible healthcare. This focus on brand management ensures that the company's most critical medical solutions remain at the forefront of clinical practice.
Prabodh Joshi - Group President, Human Resources & Corporate Communications
Prabodh Joshi, the Group President, Human Resources & Corporate Communications at Cadila Pharmaceuticals, directs organizational culture and internal messaging. Overseeing talent acquisition and employee development, the Group President, Human Resources & Corporate Communications ensures that the workforce remains aligned with the company's innovation-led mission. This leadership role involves managing corporate communications to maintain transparency and engagement across all global operations. By fostering a culture of excellence and sustainability, Prabodh Joshi directly impacts the company's ability to attract and retain top-tier talent. The Group President, Human Resources & Corporate Communications coordinates with executive leadership to ensure that internal policies support the company's long-term strategic goals. Through effective management of human capital and corporate messaging, Joshi strengthens the organizational foundation. This focus on people and communication supports the company's commitment to community well-being and professional development within the pharmaceutical industry.
Arani Chatterjee - President
Arani Chatterjee, the President at Cadila Pharmaceuticals, directs the overarching strategic initiatives and research-led growth. Overseeing the integration of clinical research with drug discovery, the President ensures that the company remains at the cutting edge of pharmaceutical innovation. This leadership role involves guiding the development of new therapies across 12 specialties to address unmet medical needs. By aligning R&D efforts with global market requirements, Arani Chatterjee directly impacts the company's ability to pioneer new drug solutions. The President coordinates with the Board and other C-suite leaders to define the company's long-term vision and market impact. Through strategic oversight of clinical research and development, Chatterjee secures the company's position as a leader in the pharmaceutical sector. This focus on innovation and research excellence supports the company's mission to make health simpler and safer for patients in over 100 countries.
Wilton Franca - President - Latam
Wilton Franca, the President - Latam at Cadila Pharmaceuticals, directs all commercial and operational activities across the Latin American region. Overseeing market entry and regulatory navigation, the President - Latam ensures that the company's pharmaceutical products reach patients in this critical growth market. This leadership role involves building local partnerships and adapting product offerings to meet regional healthcare needs. By driving regional sales and distribution, Wilton Franca directly impacts the company's global footprint and revenue growth. The President - Latam coordinates with corporate headquarters to align regional strategies with the company's broader mission of providing affordable healthcare. Through effective management of the Latin American operations, Franca strengthens the company's presence in the region. This focus on regional expansion and market adaptation supports the company's goal of delivering high-quality, accessible medical solutions to diverse populations across the globe.
Suresh Balasubramanian - President - Plantations
Suresh Balasubramanian, the President - Plantations at Cadila Pharmaceuticals, directs the management and sustainability of the company's agricultural assets. Overseeing the cultivation and sourcing of raw materials, the President - Plantations ensures that the supply chain remains consistent with the company's commitment to sustainability. This leadership role involves optimizing land use and agricultural practices to support the production of pharmaceutical ingredients. By managing these resources efficiently, Suresh Balasubramanian directly impacts the company's ability to maintain a stable and ethical supply chain. The President - Plantations coordinates with manufacturing teams to integrate natural resources into the drug development process. Through strategic oversight of plantation operations, Balasubramanian supports the company's broader mission of community well-being and environmental responsibility. This focus on sustainable sourcing ensures that the company continues to provide high-quality, reliable healthcare solutions while maintaining its commitment to ecological stewardship.
Shailendra Tyagi - President, Sales Marketing
Shailendra Tyagi, the President, Sales Marketing at Cadila Pharmaceuticals, directs the commercial outreach and market engagement strategies. Overseeing the sales force and marketing campaigns, the President, Sales Marketing ensures that the company's 850 products are effectively positioned in the global market. This leadership role involves analyzing customer feedback and market data to refine promotional strategies for 45 therapies. By driving sales performance and brand visibility, Shailendra Tyagi directly impacts the company's revenue and market penetration. The President, Sales Marketing coordinates with regional leaders to ensure that sales efforts align with local healthcare needs and regulatory environments. Through strategic management of the sales and marketing functions, Tyagi strengthens the company's competitive position. This focus on commercial excellence supports the company's mission to provide affordable and accessible healthcare solutions to patients and providers across more than 100 countries.
Explore Leadership Teams in Manufacturing
Dr. Reddy's is a leading manufacturer and supplier of high-quality, affordable Active Pharmaceutical Ingredients (APIs) aimed at generic formulations manufacturers worldwide. With a portfolio of over 250 APIs available in more than 80 countries, the company focuses on sustainability and regulatory compliance to ensure access to affordable medicines. Their services include strategic alliances, discovery and CDMO, and advanced research capabilities, making them a trusted partner in the pharmaceutical industry. Dr. Reddy's commitment to innovation and quality positions them as a preferred partner for pharma companies globally.
Company Leadership
SC
DL

Founded in 1974, Apotex is a proud Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
Company Leadership DA

JB
AA
Alkermes is a global biopharmaceutical enterprise that specialises in developing and commercialising innovative medicines for people living with complex psychiatric and neurological disorders. Headquartered in Dublin, Ireland, the company combines deep neuroscience expertise with patient‑inspired science to pursue treatments for conditions such as addiction, schizophrenia, bipolar disorder, opioid dependence and other central nervous system diseases. Its approach integrates scientific research, clinical development and specialised commercial infrastructure to deliver both marketed medicines and investigational candidates, aiming to address serious unmet medical needs and improve how chronic neurological and mental health conditions are managed.
Company Leadership ZC



SK pharmteco is a leading global contract development and manufacturing organization (CDMO) that specializes in drug development and manufacturing services for small molecules, biologics, cell, and gene therapies. The company offers a comprehensive range of services including API drug development, manufacturing, and regulatory support, catering to clients at every phase of their therapeutic programs. With a network of CGMP facilities, SK pharmteco empowers clients worldwide to bring innovative therapies to patients at any scale. Their commitment to seamless technology transfer and dedicated program management ensures successful project execution and regulatory compliance.
Company Leadership KM

DL